RELATED STORY | FDA panel rejects the use of psychedelic drug MDMA to treat patients with PTSD Lykos said the issues FDA raised in what's called a complete response letter echoed the concerns ...

The Food and Drug Administration (FDA) panel voted 10-1 against endorsing the safety of MDMA in treating PTSD, and 9-2 against its efficacy. The group cited flawed studies, unclear data and ...

The FDA has denied Lykos Therapeutics' marketing application for its post-traumatic stress disorder (PTSD) therapy based on MDMA, also known as ecstasy, in a setback for the emerging psychedelic ...

A first-of-a-kind proposal to begin using the mind-altering drug MDMA as a treatment for PTSD was roundly criticized Tuesday — a potentially major setback to psychedelic advocates who hope to ...

(MENAFN- Investor Brand Network) Last week, the U.S. Food and Drug Administration (FDA) made the decision not to approve MDMA-assisted therapy for post-traumatic stress disorder. This decision ...

Multidisciplinary Association for Psychedelic Studies (MAPS), the FDA has agreed study designs for two phase 3 studies assessing MDMA-assisted psychotherapy for patients with severe PTSD.

So that will put it at early 2021 for FDA approval,” MAPS director of communications Brad Burge told Inverse. In addition to treating PTSD patients, MDMA-assisted therapy could be used to treat ...

Kaya Holdings Advocates For Psilocybin As FDA Rejects MDMA For PTSD Treatment Kaya Holdings criticizes the FDA's rejection of MDMA therapy for PTSD, proposing psilocybin as a viable alternative ...

An FDA advisory panel voted against recommending the use of MDMA in PTSD therapy. The rejection of Lykos Therapeutics' treatment hurt stocks of firms with similar therapies in development.

Veterans Affairs Eyes Funding For New MDMA-PTSD Trial After FDA Setback PharmAla Biotech To Supply LaNeo MDMA For Mt. Sinai Clinical Trial PharmAla Biotech To Supply University Of Texas ...